Get the Stockscreener App
309.87
0.77%
-2.41
Pre-market:
309.87
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $309.87, with a volume of 1.08M.
It is down -0.77% in the last 24 hours and down -4.29% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$312.28
Open:
$313.32
24h Volume:
1.08M
Relative Volume:
0.79
Market Cap:
$59.13B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
23.77
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
+0.15%
1M Performance:
-4.29%
6M Performance:
-5.32%
1Y Performance:
+0.49%
1-Day Range:
$309.18
$316.61
1-Week Range:
$304.45
$320.24
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
309.87 | 59.13B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
869.36 | 101.36B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
222.62 | 51.55B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
85.53 | 9.53B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.76 | 651.10M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora stock heads into the open after closing flat - AD HOC NEWS
Cencora (COR) Conference Updates Keep Undervalued Case In Focus - simplywall.st
Cencora stock trades at USD 314.64 below its yearly high - AD HOC NEWS
Cencora stock holds near USD 316 after strong quarterly results - AD HOC NEWS
Cencora stock holds at USD 308.78 as specialty growth supports outlook - AD HOC NEWS
Cencora stock heads into the open after a 1.5 percent market-led gain - AD HOC NEWS
Cencora stock gains as specialty strategy supports fiscal 2027 outlook - AD HOC NEWS
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 - finance.yahoo.com
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference - finance.yahoo.com
Cencora, Inc. (COR) Stock Analysis: Unveiling a 19.6% Potential Upside in the Healthcare Distribution Sector - DirectorsTalk Interviews
Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value? - finance.yahoo.com
Cencora Inc. stock gains after raising full-year EPS guidance - AD HOC NEWS
Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch? - finance.yahoo.com
What Makes the Latest Cencora (COR) Story Different? - Kalkine Media
Cencora Inc. stock eases after insider sale while earnings grow - AD HOC NEWS
Cencora Inc. stock eases after recent insider share sale - AD HOC NEWS
Cencora, Inc. (COR) Stock Forecasts - finance.yahoo.com
Cencora (NYSE: COR) director sells $411K in shares - Stock Titan
Cencora Inc. stock gains after beating quarterly earnings estimates - AD HOC NEWS
Cencora Inc Hired Firms, 2026 - OpenSecrets
Cencora (NYSE: COR) director files notice for potential stock sale via Merrill Lynch - Stock Titan
Cencora, Inc. (COR) Stock Analysis: Strong Buy Ratings And A 14.85% Upside Potential - DirectorsTalk Interviews
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Benzinga
Cencora (COR) ex-officer lines up new stock sale - Stock Titan
Cencora (COR) Stock Forecast and Price Target 2026 $COR - MarketBeat
Cencora stock heads into the open after a 0.1% dip - ad-hoc-news.de
Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? - Yahoo Finance
Cencora Inc. stock dips after RBC reiterates cautious price target - ad-hoc-news.de
Is Cencora Stock Underperforming the Dow? - Yahoo Finance
Cencora stock price target maintained at $330 by RBC Capital By Investing.com - Investing.com Australia
Cencora stock heads into the open after a modest decline - ad-hoc-news.de
Cencora stock holds firm after RBC keeps $330 target - ad-hoc-news.de
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cencora stock price target maintained at $330 by RBC Capital - Investing.com Canada
Cencora, Inc. (COR) Stock Analysis: Robust Growth in Medical Distribution with an 11.59% Upside Potential - DirectorsTalk Interviews
Cencora Inc. stock gains on solid fiscal 2026 momentum - ad-hoc-news.de
Why Cencora (COR) Is Getting Attention Today - simplywall.st
Cencora’s New Cell and Gene Services Might Change The Case For Investing In Cencora (COR) - simplywall.st
Cencora Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Former Cencora (NYSE: COR) leader lines up another stock sale - Stock Titan
Cencora Inc. stock gains on new cell and gene therapy service and strong guidance - ad-hoc-news.de
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Cencora Launches Cell and Gene Therapy Enablement for Health Systems - Yahoo Finance
Cencora (COR) Unveils Cell And Gene Therapy Enablement Service - simplywall.st
What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders - Yahoo Finance
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen - Yahoo Finance
Cencora Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs - BioBuzz
Artisan Sold Cencora (COR) as Earnings Momentum Slowed - Yahoo Finance
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):